Holen Sie sich die Stockscreener-App
387.70
0.57%
-2.24
Handel nachbörslich:
387.70
Schlusskurs vom Vortag:
$389.94
Offen:
$390.82
24-Stunden-Volumen:
206.97K
Relative Volume:
0.62
Marktkapitalisierung:
$10.37B
Einnahmen:
$2.59B
Nettoeinkommen (Verlust:
$168.80M
KGV:
63.82
EPS:
6.0748
Netto-Cashflow:
$357.20M
1W Leistung:
+2.02%
1M Leistung:
+17.13%
6M Leistung:
+39.24%
1J Leistung:
+32.02%
1-Tages-Spanne:
$382.10
$392.29
1-Wochen-Bereich:
$373.40
$396.23
52-Wochen-Spanne:
$236.73
$396.23
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
387.70 | 10.07B | 2.59B | 168.80M | 357.20M | 6.0748 |
ABT
Abbott Laboratories
|
112.47 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.69 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
91.23 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.84 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.21 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Return on invested capital % of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA - TradingView
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - Yahoo Finance
Bio-Rad (BIO) Quarter in Focus: Profit Per Share Clears Its Benchmark for the Current Session - vinanet.vn
Bio-Rad Laboratories Inc (BIO) Shares Surge 3.4% -- What GF Scor - GuruFocus
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building? - Yahoo Finance
Westport Asset Management Inc. Invests $881,000 in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at $365.68 By Investing.com - Investing.com Nigeria
Bio-Rad Laboratories (NYSE:BIO) Reaches New 12-Month HighShould You Buy? - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at $365.68 - Investing.com
Bio Rad Laboratories Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
S&P 500 Futures Decline In Premarket Trading; Bio-Rad Labs A, Fabrinet Lag - Moomoo
Sickle Cell Anemia Testing & Screening Industry Trends & Growth - SNS Insider
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Challenging Market with Innovative Diagnostics - DirectorsTalk Interviews
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost? - Yahoo Finance
Bio-Rad Laboratories (NYSE:BIO) Upgraded to Hold at Zacks Research - MarketBeat
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
First Trust Advisors LP Has $424,000 Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock forecasts - Yahoo Finance UK
Bio Rad Laboratories (BIO) Issues Flat Revenue Guidance, Is It Too Far Above Fair Value? - Sahm
Bio-Rad (BIO) Q2 2026 Earnings Call Transcript - aol.com
Bio-Rad Laboratories (NYSE:BIO) Hits New 52-Week HighHere's What Happened - MarketBeat
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock - Yahoo Finance
Bio-Rad Laboratories (BIO) Stock Analysis: Exploring a Potentially Overvalued Healthcare Giant - DirectorsTalk Interviews
Bio Rad Laboratories (BIO) Earnings And Guidance Put Fair Value Back In Focus - Yahoo Finance
Technical Reactions to BIO Trends in Macro Strategies - Stock Traders Daily
Assenagon Asset Management S.A. Acquires 85,393 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at 352.86 USD - Investing.com
Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
US$329That's What Analysts Think Bio-Rad Laboratories, Inc. (NYSE:BIO) Is Worth After These Results - Moomoo
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $390 - Moomoo
Bio-Rad's FCPA Review Gets Picked Over at Trial - Law.com
Bio-Rad Laboratories, Inc. $BIO Shares Bought by California State Teachers Retirement System - marketbeat.com
BIO-RAD LABORATORIES, INC. : WELLS FARGO RAISES TARGET PRICE TO $330 FROM $310 - webull.com
BIO Maintained by Citigroup -- Price Target Raised to $330 - GuruFocus
Is Bio-Rad Laboratories Inc (BIO) Overvalued After 4.5% Rally? G - GuruFocus
Citigroup Increases Bio-Rad Laboratories (NYSE:BIO) Price Target to $330.00 - MarketBeat
BIO Maintains Rating by Wells Fargo -- Price Target Raised to $3 - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Bio-Rad Laboratories (NYSE:BIO) Stock - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Sets New 52-Week High on Earnings Beat - marketbeat.com
Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
BIO SWOT Analysis: Financial Resilience Amidst Market Challenges Revealed in 10-Q Filing - GuruFocus
AUG 04 (REUTERS)BIO-RAD Q2 EPS USD 13.85. - Moomoo
Amundi Has $10.81 Million Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Earnings: Modest Sequential Improvement, but Full-Year Guidance Ranges Remain Wide - Morningstar
Bio-Rad Laboratories Inc (BIO) (Q2 2026) Earnings Call Highlights: Digital PCR Surges 20%+ as ... By GuruFocus - Investing.com Canada
BIO Looks 4.8% Overvalued on GF Value™ Amid Restructuring Plans - GuruFocus
Bio-Rad Laboratories Q2 Earnings Call Highlights - MarketBeat
Bio-Rad: Q2 Earnings Snapshot - Barchart.com
Is Bio-Rad Laboratories Inc (BIO) Overvalued After Q2 Earnings B - GuruFocus
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):